Numeric Investors LLC acquired a new stake in Puma Biotechnology Inc (NYSE:PBYI) during the fourth quarter, Holdings Channel reports. The fund acquired 37,200 shares of the biopharmaceutical companys stock, valued at approximately $1,142,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PBYI. Tower Research Capital LLC TRC boosted its stake in shares of Puma Biotechnology by 253.3% in the third quarter. Tower Research Capital LLC TRC now owns 2,427 shares of the biopharmaceutical companys stock valued at $163,000 after buying an additional 1,740 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Puma Biotechnology by 142.4% in the second quarter. Legal & General Group Plc now owns 6,142 shares of the biopharmaceutical companys stock valued at $183,000 after buying an additional 3,608 shares during the last quarter. Ardsley Advisory Partners acquired a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $201,000. Laurion Capital Management LP acquired a new stake in shares of Puma Biotechnology during the third quarter valued at approximately $208,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Puma Biotechnology during the fourth quarter valued at approximately $225,000. Hedge funds and other institutional investors own 80.98% of the companys stock.

Shares of Puma Biotechnology Inc (NYSE:PBYI) traded up 3.37% during trading on Monday, hitting $41.40. 210,498 shares of the stock traded hands. The firms market capitalization is $1.53 billion. Puma Biotechnology Inc has a 1-year low of $19.74 and a 1-year high of $73.27. The firm has a 50-day moving average of $35.26 and a 200-day moving average of $44.21.

Puma Biotechnology (NYSE:PBYI) last issued its earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($2.04) earnings per share for the quarter, missing analysts consensus estimates of ($1.92) by $0.12. On average, equities analysts forecast that Puma Biotechnology Inc will post ($8.32) earnings per share for the current year.

PBYI has been the subject of several recent research reports. Citigroup Inc set a $88.00 target price on shares of Puma Biotechnology and gave the company a buy rating in a research report on Tuesday, January 3rd. JPMorgan Chase & Co. set a $89.00 target price on shares of Puma Biotechnology and gave the company a buy rating in a research report on Monday, November 14th. Royal Bank of Canada reiterated a sector perform rating and set a $17.00 target price (down previously from $48.00) on shares of Puma Biotechnology in a research report on Thursday, March 2nd. Credit Suisse Group AG reiterated an outperform rating and set a $111.00 target price on shares of Puma Biotechnology in a research report on Tuesday, November 15th. Finally, Stifel Nicolaus reiterated a buy rating and set a $88.00 target price on shares of Puma Biotechnology in a research report on Wednesday, November 30th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $73.50.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 10,202 shares of the firms stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $33.24, for a total value of $339,114.48. Following the sale, the insider now owns 4,179,798 shares in the company, valued at $138,936,485.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Richard Paul Bryce sold 2,293 shares of the firms stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $33.24, for a total transaction of $76,219.32. Following the completion of the sale, the senior vice president now owns 29,237 shares in the company, valued at approximately $971,837.88. The disclosure for this sale can be found here. Insiders sold 15,503 shares of company stock worth $511,078 in the last 90 days. Company insiders own 22.70% of the companys stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

View post:
The Numeric Investors LLC Purchases New Position in Puma Biotechnology Inc (PBYI) - Petro Global News 24